Rationale: The activated leukocyte cell adhesion molecule (ALCAM) is a cluster of differentiation 6 ligand that is important for stabilizing the immunological synapse and inducing T-cell activation and proliferation.
Allergic asthma is a common chronic respiratory disease involving the T-helper cell type 2 (Th2) immune response. Th2-type cytokines released by cluster of differentiation 4-positive (CD4 1 ) Th2 cells are the main inducers of asthma (1) (2) (3) (4) . Repeated exposure to allergens stimulates the release of IL-4, IL-5, and IL-13, which activate IgE and eosinophilic responses. This results in airway remodeling, including thickening of airway walls, airway hyperresponsiveness (AHR), and excess mucus secretion (5) (6) (7) (8) . Therefore, controlling CD4
1 Th2 cells is critical for asthma management.
T cells are activated by interactions between T-cell receptors and their cognate antigenic peptide major histocompatibility complex (MHC) on antigen-presenting cells. In addition, interactions between costimulatory molecules on T cells and dendritic cells (DCs) are required for formation of the immunological synapse (9) (10) (11) .
Activated leukocyte cell adhesion molecule (ALCAM; also known as CD166) belongs to the immunoglobulin superfamily and is composed of five immunoglobulinlike domains (12) . It is expressed in various cell types, including neurons, fibroblasts, endothelial cells, and keratinocytes (13, 14) . ALCAM plays important roles in leukocyte extravasation, stabilization of the immunological synapse, T-cell activation and proliferation, and tumor progression and metastasis (15) (16) (17) . As a ligand for CD6, a type I membrane protein that functions in T-cell adhesion and costimulation, ALCAM is thought to be important for initiating and sustaining the T-cell immune response (18, 19) . A recent study demonstrated that ALCAM and CD6 form a receptor-ligand complex that is essential for early DC-T-cell binding and for sustaining DC-induced T-cell proliferation (16) . The effects of ALCAM in delayed-type hypersensitivity have also been established in the S100-induced inflammatory response (20) .
Because ALCAM is associated with hypersensitivity and T-cell proliferation through the formation of the immunological synapse, we hypothesized that ALCAM might be involved in allergic asthma, which is a type I hypersensitivity disease characterized by a CD4
1 Th2-cell immune response. To test this hypothesis, we established an ovalbumin (OVA)-induced allergic asthma model in ALCAMdeficient (ALCAM 2/2 ) and wild-type (WT) mice and compared the inflammatory responses. We also conducted antibody treatment to evaluate the therapeutic effects of ALCAM. Furthermore, we investigated genetic variations in ALCAM and compared its amounts in serum and sputum samples obtained from children with asthma and from control subjects. Some of the results of these studies were previously reported in the form of an abstract (21) .
Methods
Additional details of the methods are provided in the online supplement.
Mice C57BL/6 mice were purchased from ORIENT BIO, and female mice (6-8 wk old) were used for experiments. ALCAM 2/2 and OT-II mice were purchased from The Jackson Laboratory. For the ALCAM 2/2 OVA model, OT-II mice were backcrossed with ALCAM 2/2 mice; OT-II mice served as WT controls. C57BL/6 WT and ALCAM 2/2 mice were used for the house dust mite (HDM) model. Animals were housed under specific pathogen-free conditions. These studies were approved by the Institutional Animal Care and Use Committee of the University of Yonsei College of Medicine (reference no. 2013-0021).
Allergen Sensitization and Challenge
Mice were immunized by intraperitoneal injection of 100 mg of OVA (chicken egg albumin fraction V; Sigma-Aldrich) and 2 mg of aluminum hydroxide (Imject Alum Adjuvant; Pierce Biotechnology) on Days 0 and 14. After anesthetization with isoflurane, mice underwent intranasal challenge with 50 mg of OVA on Days 28, 29, and 30. Age-and sex-matched mice were treated with saline alone as a control. Mice were killed 24 hours after the final challenge, and their BAL fluid (BALF), sera, lungs, and spleen were collected and analyzed.
Bone Marrow-derived Dendritic Cell Culture and Antigen Pulsing Bone marrow cells were collected from the tibias and femurs of ALCAM 2/2 and WT mice and cultured in RPMI 1640 medium containing 10% fetal bovine serum and 1% penicillin-streptomycin (HyClone Laboratories) supplemented with 20 ng/ml recombinant mouse granulocytemacrophage colony-stimulating factor and IL-4 (R&D Systems) for 7 to 9 days. For antigen pulsing, cells were stimulated overnight with 100 mg/ml OVA and 1 mg/ml LPS (Sigma-Aldrich). DCs without antigen pulsing served as controls. Costimulatory molecule expression and DC differentiation and maturation were confirmed by flow cytometry after cells were labeled with allophycocyanin (APC)-conjugated anti-CD11c, APCconjugated anti-CD40, fluorescein isothiocyanate-conjugated anti-CD86, and phycoerythrin-conjugated anti-MHC class II antibodies (eBioscience) before use.
Adoptive Transfer Experiments
OT-II mice were sensitized with OVA and alum on Days 0 and 14, as described above. Bone marrow-derived dendritic cells (BMDCs) (1 3 10 6 ) were adoptively transferred to mice by intratracheal injection on Days 28 and 30 after anesthesia with tiletamine/zolazepam and xylazine. Mice were killed 24 hours after the last injection, and samples were harvested. To analyze the effect of ALCAM on allergen priming, BMDCs (1 3 10 6 ) were adoptively transferred to mice intranasally on Days 0 and 7. After 7 days, draining lymph node (DLN) samples were collected and cultured for 5 days in either the presence or absence of OVA. Cell proliferation was measured by using the Cell Counting Kit-8 (CCK-8; Dojindo Molecular Technologies) assay and flow cytometric analysis after labeling with APC-conjugated anti-Ki67 and peridininchlorophyll-protein complex/cyanine 5.5-conjugated anti-CD4.
In Vivo Antibody Treatment WT mice were sensitized as described above and intranasally treated with 10 mg of anti-ALCAM antibody (H-108; Santa Cruz Biotechnology) or normal rabbit IgG 30 minutes before each OVA challenge. 2/2 mice challenged with OVA or treated with PBS (control group, n = 6-9; OVA-treated group, n = 10-12). Normally distributed data were analyzed using Student's t test, and nonnormally distributed data were analyzed using the Mann-Whitney U test. Results are presented as mean 6 SEM (A; B; IL-4 and -5 in C; IL-4 and -5 in D; and F) or median (interquartile range) (IL-13 and MUC5AC in C; IL-13 in D; and E). Scale bars, 200 mm (top) and 100 mm (bottom). *P , 0.05; **P , 0.01; ***P , 0.001. CCL = chemokine C-C motif ligand; Eos = eosinophil; Lym = lymphocyte; Mac = macrophage; Neu = neutrophil.
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Subjects
Totals of 227 (asthma, n = 156; control subjects, n = 71) and 112 (asthma, n = 54; control subjects, n = 48) children were enrolled in the study for analyses of serum and sputum ALCAM concentrations, respectively. Asthma was diagnosed according to the guidelines of the American Thoracic Society (22) . Additional details can be found in the online supplement.
Statistical Analysis
Data are presented as the mean 6 SEM. ANOVA was evaluated by Student's t test. P , 0.05 was considered statistically significant. Statistical comparisons between patients with asthma and control subjects were performed using the Mann-Whitney U test. Mild, moderate, and severe asthma subgroups were compared by ANOVA and the Kruskal-Wallis test in serum and sputum samples, respectively. Multiple comparisons were performed using Dunn's method. Correlations between ALCAM concentrations and pulmonary function parameters, including PC20 (i.e., concentration of methacholine causing a 20% decrease in FEV 1 from the postnebulized saline solution value), were evaluated by Spearman's test. A chi-square test was used for categorical data, such as sex. Data were analyzed using IBM SPSS Statistics version 20 (IBM).
Results
ALCAM Concentrations Are Altered in a Mouse Model of OVA-induced Asthma
To investigate the involvement of ALCAM in allergic asthma, we established a mouse model of OVA-induced asthma, and we compared ALCAM concentrations in BALF, serum, and lung tissue with those in untreated control mice ( Figure 1A ). ALCAM concentrations were increased in BALF and serum ( Figure 1B) and decreased in lung tissue ( Figures 1C and  1D ) by OVA treatment.
To reconcile these conflicting observations, we evaluated a disintegrin and metalloprotease 17 (ADAM17) expression in lung tissue because it was recently shown to be the protease responsible for ALCAM shedding (23) (24) (25) . ADAM17 expression was upregulated in the lung tissue of the OVA-treated group (see Figure E1A in the online supplement). To investigate the association between ADAM17 and ALCAM concentrations, splenocytes from WT mice were cultured with the anti-ADAM17 antibody. ALCAM concentration in the supernatant was decreased by antibody treatment relative to that in cells treated with a control antibody in the presence of OVA and IL-2 ( Figure E1B ). Furthermore, anti-ADAM17 antibody treatment reduced ALCAM shedding in a dose-dependent manner ( Figure E1C ). In addition, we observed an increase in the expression of ALCAM on CD11c
1 CD11b 1 and MHCII
1
DCs in OVA-treated mouse lung tissue (62.6% vs. 49.8% in controls) ( Figure 1E ).
ALCAM Alters Th2 Response in OVA-induced Asthma
To investigate the contribution of ALCAM to allergic asthma, ALCAM 2/2 and WT mice were sensitized and challenged with 1 CD4 1 T-cells and CD11b 1 CD11c 1 DCs were sorted from splenocytes of OVA-sensitized WT and ALCAM 2/2 mice. DCs were then subjected to g-irradiation (2,000 rad) and cocultured with T cells in the absence or presence of IL-2 and OVA. After 5 days, proliferation was evaluated by CCK-8 assay. WT T-cell/DC cocultures without OVA treatment served as a control. (C) Isolated CD3
1 CD4 1 T-cells of WT and ALCAM 2/2 mice were mixed and stained with carboxyfluorescein succinimidyl ester (CFSE-A), and cells were cocultured with the indicated type of g-irradiated DCs. After 5 days, T-cell proliferation was measured by flow cytometry. Representative plots are shown on the left (from generations 0 to 7), and quantitative analysis of T-cell proliferation is shown on the right. Results represent the mean 6 SD of two independent experiments using four replicate samples. *P , 0.05; **P , 0.01; ***P , 0.001 (Student's t test). N.S. = not significant. 
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OVA, and their inflammatory responses were compared. Before comparison, a complete blood cell count was conducted to ascertain whether ALCAM 2/2 mice showed basal defects in leukocyte cell number. This result confirmed the absence of fundamental defects in the ALCAM 2/2 mice (Table E1) . Inflammatory cell counts in BALF were elevated in WT mice treated with OVA, accompanied by a predominance of eosinophils (Figure 2A) . AHR was then induced by increasing doses of methacholine in OVA-treated mice ( Figure 2B ). This was accompanied by increased mRNA concentrations of Th2-type cytokines IL-4, IL-5, and IL-13 and of the mucus hypersecretion mucin 5AC gene (MUC5AC) in lung tissue ( Figure 2C ), as well as increased IL-4, IL-5, and IL-13 concentrations in BALF ( Figure 2D ).
Th2-cell associated chemoattractant CCL17 and CCL24 concentrations in lung homogenate, serum total IgE, and OVA-specific IgE concentrations were also elevated in the OVA-treated group ( Figures  2E and 2F) , whereas hematoxylin and eosin (H&E) staining and periodic acid-Schiff (PAS) staining of lung tissue described characteristics of exacerbated inflammatory lung tissue (Figures 2G and 2H) . By contrast, OVA-treated ALCAM 2/2 mice showed reduced inflammatory responses as compared with those observed in their WT counterparts in terms of inflammatory cell counts, AHR, Th2-type cytokines, CCL17, CCL24, and total OVA-specific IgE concentrations, as well as histological analyses of H&E-and PAS-stained lung tissue (Figures 2A-2H ). In addition, the number of CD3
1
CD4
1 T cells and the expression of type 2 cytokines from the T cells were decreased in the splenocytes of asthmatic ALCAM 2/2 mice as compared with these levels in asthmatic WT mice ( Figure E2 ).
Ex vivo experiments using splenocytes from WT and ALCAM 2/2 mice revealed higher concentrations of ALCAM in the supernatant of OVA-treated WT splenocytes than those observed in untreated control cultures ( Figure E3A ). In addition, higher concentrations of IL-5 and IL-13 were detected in the supernatant of OVA-treated splenocytes from WT mice than those observed in ALCAM 2/2 mice ( Figures E3B and E3C ). Because type 2 innate lymphoid cells (ILC2s) are also sources of type 2 cytokine production, we investigated the effect of ALCAM on alternations in the ILC2 population in the mouse model of OVA-induced asthma. We were unable to determine the involvement of ILC2, because asthmatic WT mice showed no alterations in ILC2 populations in lung and BALF samples ( Figure E4 ). Therefore, these results suggested that the decreased inflammation was caused not by alterations in ILC2 but rather by Th2 cells.
ALCAM Alters Th2 Response in a Mouse Model of HDM-induced Asthma
To determine whether the effects of ALCAM are limited to asthma induced by OVA, we established an HDM-induced allergic asthma model in ALCAM 2/2 and WT mice ( Figure E5A ). Similar to results observed in the OVA-induced asthma model, ALCAM concentrations were elevated in BALF and decreased in the lung tissue of HDM-exposed mice as compared with concentrations observed in unexposed WT mice (Figures E5B and E5C) . The induction of allergic asthma by HDM extract was confirmed by inflammatory cell counts in BALF, AHR, and Th2-type cytokine and total IgE concentrations in serum, as well as by histological analysis of H&E-stained lung tissue samples ( Figures  E5D-E5H ). In addition, inflammatory responses were reduced in ALCAM 2/2 mice relative to those in WT mice exposed to HDM (Figures E5D-E5H) .
ALCAM Expressed by DCs Modulates T-Cell Proliferation
Given that ALCAM is important for T-cell activation and proliferation, we evaluated the proliferation of splenocytes from OVAsensitized WT and ALCAM 2/2 mice. In the presence of OVA and IL-2, WT cells showed higher rates of proliferation than DCs were isolated from the splenocytes of WT and ALCAM 2/2 mice, respectively, for coculture experiments. ICOSL, MHC class II, CD80, and CD86 expression on DCs was analyzed, confirming the absence of defects in DCs from ALCAM 2/2 mice ( Figure  E6A ). Coculture experiments revealed that ALCAM deficiency in T cells did not affect T-cell proliferation; however, the rate of proliferation was lower in T cells cocultured with ALCAM 2/2 DCs than in those cocultured with ALCAM 1/1 DCs ( Figure 3B ). To confirm these observations, proliferation was evaluated by labeling cells with carboxyfluorescein succinimidyl ester, resulting in detection of proliferation in 46.5% of T cells cocultured with ALCAM
1/1
DCs as compared with 27.7% of those cocultured with ALCAM 2/2 DCs ( Figure 3C ). To validate the specificity of the ALCAM-CD6 responses, we blocked CD6 on T cells in coculture experiments. In the presence of OVA, T cells cocultured with ALCAM 1/1 DCs showed significant decreases in proliferation upon treatment with the anti-CD6 antibody. However, we observed a lesser decrease in proliferation in T cells cocultured with ALCAM
2/2
DCs upon treatment with the anti-CD6 antibody, suggesting the specificity of the ALCAM-CD6 interaction ( Figure E7 ). To assess the role of ALCAM on DCs in vivo, OT-II mice were sensitized as described and then intratracheally injected with OVA-pulsed BMDCs to induce allergic asthma ( Figure 4A) . Comparison of CD40, CD86, and MHC class II expression on BMDCs from ALCAM 2/2 mice with that in WT mice showed no significant differences ( Figure E6B ). OT-II mice injected with OVA-pulsed BMDCs from WT mice showed higher inflammatory cell counts in BALF and enhanced AHR after methacholine challenge ( Figures 4B  and 4C ). In addition, in mice injected with OVA-pulsed WT BMDCs, we observed upregulation of IL-4, IL-5, and IL-13 and MUC5AC mRNA expression in lung tissue; IL-4, IL-5, and IL-13 protein concentrations in BALF; and serum total IgE and OVA-specific IgE concentrations (Figures 4D-4F) . By contrast, OT-II mice injected with OVA-pulsed BMDCs from ALCAM 2/2 mice showed a reduced inflammatory response as compared with that observed in mice injected with OVA-pulsed BMDCs from WT mice, including fewer inflammatory cells in BALF; decreased AHR and IL-4, IL-5, IL-13, and MUC5AC expression; and a lower concentration of total IgE (Figures 4B-4F ). H&E staining of lung tissue sections also revealed reduced inflammation in mice injected with OVA-pulsed BMDCs from ALCAM 2/2 mice ( Figure 4G ). To address the role of ALCAM on DCs during allergen priming, OVA-pulsed BMDCs from ALCAM 2/2 or WT mice were adaptively transferred to OT-II mice, and 7 days later, DLNs from the mice BMDC-treated mice, indicating the involvement of ALCAM in allergen priming ( Figure E8B ).
ALCAM Deficiency Decreases the Trafficking of DCs and T Cells to Airways
Because previous studies highlighted a critical role for ALCAM expression by endothelial cells in regulating the trafficking of T cells into the central nervous system in a mouse model of multiple sclerosis (26), we investigated the trafficking of T cells and DCs in airways. Our results showed that DC numbers in BALF and lung tissue were significantly reduced in asthmatic ALCAM 2/2 mice as compared with those in asthmatic WT mice ( Figure 5A ). T-cell counts in BALF and lung tissue also showed a tendency toward a decrease in asthmatic ALCAM 2/2 mice as compared with that observed in asthmatic WT mice ( Figure 5B ).
Anti-ALCAM Antibody Treatment Reduces Inflammation in an OVA-induced Asthma Model
We then investigated the therapeutic effects associated with anti-ALCAM antibody treatment. WT mice were administered the anti-ALCAM antibody 30 minutes before OVA challenge ( Figure 6A ). Antibody treatment reduced the inflammatory Figures 6G and 6H ). Ex vivo experiments using splenocytes from sensitized WT mice confirmed that ex vivo anti-ALCAM antibody treatment inhibited T-cell proliferation ( Figure 6I ). These results demonstrated that the anti-ALCAM antibody exhibited therapeutic effects in an OVA-induced allergic asthma model.
Serum and Sputum ALCAM Concentrations and Genetic Variations in Pediatric Asthma
We examined ALCAM concentrations in the serum and sputum of pediatric patients with asthma. The clinical characteristics of the study subjects are summarized in Table 1 . In both fluids, ALCAM concentrations were higher in children with asthma than in normal control subjects (serum, 13. 7B) . Furthermore, serum and sputum ALCAM concentrations were higher in children with more severe asthma ( Figures 7C and 7D) , and serum ALCAM concentrations were inversely correlated with PC20 in patients with asthma (r = 20.294; P , 0.001; data not shown).
We screened for nonsynonymous variants of the ALCAM gene by highthroughput resequencing to investigate genetic susceptibility to allergic asthma, and we identified four low-frequency nonsynonymous variants. Among them, the p.N258S variant conferred protection against allergic asthma ( Table 2) .
Discussion
In the present study, we demonstrated that ALCAM acts on antigen-presenting cells to stimulate the Th2 response, thereby influencing the development of allergic asthma. In our WT mouse model of OVA-induced allergic asthma, ALCAM concentrations were increased in BALF and serum relative to those in control mice. Consistent with these observations, higher ALCAM concentrations were also detected in the serum and sputum of patients with asthma than those in control subjects, suggesting the possible use of ALCAM as a biomarker for allergic asthma. In addition, the p.N258S variant of ALCAM was found to exhibit protective effects against allergic asthma in children.
Contrary to the observations in BALF and serum, ALCAM concentrations in mouse lung tissue were lower in mice with OVA-induced allergic asthma. Researchers in a previous study similarly reported that ALCAM concentrations were elevated in serum and ascites but decreased in ascitic cell lysates, leading to the conclusion that loss of surface ALCAM expression is associated with an increase in cytoplasmic ALCAM concentrations (27) . In a study of patients with epithelial ovarian cancer, investigators found that decreased membrane ALCAM expression is a marker for poor outcomes (28) . Downregulation of ALCAM expression in tissue has been linked to a malignant phenotype and poor prognosis in breast cancer (29) . However, serum concentrations of ALCAM have been shown to be upregulated in various types of cancer, including colorectal carcinoma and breast, pancreatic, esophageal, and gastric cancers (30) (31) (32) (33) (34) . We speculate that reductions in ALCAM expression in lung tissue underlie the increases in ALCAM concentrations in BALF and serum in allergic asthma.
The proteolytic release of cell surface protein extracellular domains-a process known as shedding-is an important mechanism for regulating protein function. ADAM17 is a well-known sheddase involved in cell development, adhesion, and differentiation, as well as in the migration of leukocytes and tumor cells (35, 36) . Recent studies also indicate its major role as a sheddase for tumor necrosis factor-a and ligands of epidermal growth factor receptor, cell adhesion proteins, and the IL-6 receptor in inflammatory lung disease (37) (38) (39) . ADAM17 is also responsible for the shedding of ALCAM extracellular domains (23) (24) (25) . In the present study, we found that ADAM17 expression was elevated in OVA-challenged mice and that treatment with the anti-ADAM17 antibody inhibited ALCAM release into the supernatant of OVA-treated splenocytes from WT mice. On the basis of these findings, we hypothesize that in the initial phase of inflammation, ALCAM induces T-cell activation and proliferation. Then, as the inflammatory response proceeds, ADAM17 is upregulated and cleaves membrane-bound ALCAM, causing an increase in soluble ALCAM concentrations in the serum and BALF and a concomitant decrease in ALCAM concentrations in lung tissue. However, the precise role of soluble ALCAM has not yet been elucidated, although previous studies suggest that soluble ALCAM negatively regulates ALCAM function (14, (40) (41) (42) . Soluble fusion proteins consisting of the extracellular regions of CD6 or CD166 are known to inhibit T-cell responses (16, 43, 44) . A previous study also suggested that soluble ALCAM is involved in ALCAM-CD6 interactions (45) . Therefore, ALCAM and soluble ALCAM might play distinct roles in the development of inflammation. Additional studies are needed to clarify the function of soluble ALCAM beyond its role as a biomarker in allergic asthma. Although ALCAM expression was downregulated in total lung tissue lysates, we detected an increase in ALCAM expression in lung tissue DCs, the main antigen-presenting cells. This discordance in ALCAM expression between lung DCs and total lung lysate suggests the need for additional studies to evaluate the role of ALCAM in asthma, given that it is expressed by diverse cell types, including neurons, fibroblasts, keratinocytes, and endothelial and epithelial cells and is involved not only in immunological synapse formation but also in leukocyte extravasation, migration, hematopoiesis, and tumor progression and metastasis (15) (16) (17) 46) . ALCAM 2/2 mice showed reduced inflammatory responses as compared with those observed in WT mice upon OVA treatment. In addition, T cells cocultured with ALCAM 2/2 DCs showed a lower proliferation rate than those cocultured with ALCAM 1/1 DCs. Consistent with these results, a weaker immune response was observed in mice injected with OVA-pulsed ALCAM 2/2 BMDCs than in those that received OVA-pulsed ALCAM 1/1 BMDCs. These results demonstrated that ALCAM on DCs played a pivotal role in regulating T-cell proliferation and resulted in decreased inflammation. However, we could also observe the involvement of ALCAM in T-cell and DC trafficking of T cells and DCs into airways. Although this study was focused on the effect of ALCAM on T-cell proliferation, our findings suggest that the decreased inflammation observed in asthmatic ALCAM 2/2 mice was due partly to the decreased trafficking of T cells and DCs into airways. Administration of the anti-ALCAM antibody had therapeutic effects in our OVA-induced allergic asthma model. We speculate that the effects of the ALCAM antibody include its binding to DCs and consequent suppression of immunological synapse formation. This can be addressed by evaluating ALCAM function in specific cell types using conditional knockout mice, which might allow results providing a clear basis for the use of the anti-ALCAM antibody to treat allergic asthma.
In conclusion, to our knowledge, this is the first report providing molecular and genetic evidence for a critical role of ALCAM in the development of allergic asthma. Our findings indicate that ALCAM can be a potential therapeutic target in allergic asthma. n
